KB-R7785
KB-R7785 is a matrix metalloproteinase (MMP) inhibitor, which improves insulin sensitivity by inhibiting TNF-α production. KB-R7785 can be used for diabetes research. KB-R7785 has a protective efficacy against focal cerebral ischemia[1][2].
Product Specifications
CAS Number
168158-16-5
UNSPSC
12352005
Target
MMP
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/kb-r7785.html
Purity
99.90
Solubility
DMSO : 20 mg/mL (ultrasonic)
Smiles
ONC([C@@H](C)[C@@H](CC(C)C)C(N[C@@H](C1=CC=CC=C1)C(NC)=O)=O)=O
Molecular Formula
C18H27N3O4
Molecular Weight
349.42
References & Citations
[1]Morimoto Y, et al. KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production. Life Sci. 1997;61 (8) :795-803.|[2]Jiang X, et al. Matrix metalloproteinase inhibitor KB-R7785 attenuates brain damage resulting from permanent focal cerebral ischemia in mice. Neurosci Lett. 2001 Jun 1;305 (1) :41-4.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNUB1555-100 1x 100 µL
Ep-CAM / CD326 (Epithelial Marker) (EGP40/1555R), 0.2mg/mL
Sign In for Pricing
View Details 
